Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2024-01-29 Share Issue/Capital Cha…
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Gedeon Richter becomes strategic investor of Formycon via equity investment
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that Gedeon Richter has become a strategic investor in Formycon AG through a cash capital increase, acquiring 9.08% of shares for EUR 82.84 million. This transaction involves the issuance of new shares and the exclusion of shareholder subscription rights, which directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV). Since it details the specifics of the financing, it is more specific than a general Regulatory Filing (RNS).
2024-01-29 English
Formycon resolves on cash capital increase of EUR 82.84 million all new shares were subscribed by Gedeon Richter as new strategic investor
Capital/Financing Update Classification · 98% confidence The document is an 'Ad-hoc' announcement dated January 29, 2024, disclosing an 'inside information' pursuant to Article 17 of Regulation (EU) No 596/2014 (MAR). The core content details a resolution by Formycon AG to execute a 'cash capital increase of EUR 82.84 million' through the issuance of new shares subscribed by a strategic investor (Gedeon Richter). This action directly relates to changes in the company's share structure and fundraising activities. This fits the definition of 'Capital/Financing Update' (CAP) as it describes a specific corporate action involving capital structure change and fundraising, rather than a general regulatory filing (RNS) or a report itself.
2024-01-29 English
Formycon Ranibizumab Biosimilar FYB201/CIMERLI achieved a market share of 38% in the United States in December 2023
Earnings Release Classification · 100% confidence The document is a press release dated January 18, 2024, announcing market share and sales figures for a biosimilar product (CIMERLI®) in the US, referencing data from a commercialization partner (Coherus BioSciences). It contains key performance indicators (market share, doses sold, cumulative sales) and commentary from the CEO. This structure strongly aligns with an Earnings Release (ER), which provides initial announcements of periodical financial results and key highlights, rather than a comprehensive Interim Report (IR) or Annual Report (10-K). The document is short and focused on recent performance metrics, fitting the definition of an ER. Q4 2023
2024-01-18 English
Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference
Report Publication Announcement Classification · 99% confidence The document is a press release dated January 4, 2024, announcing that the CEO of Formycon AG will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. It also mentions that management will host one-on-one investor meetings. This type of announcement, which details participation in an external industry conference where company strategy and pipeline might be discussed, is best classified as an Investor Presentation (IP) announcement or related material, as it is geared towards investor engagement outside of standard regulatory reporting. However, since the document itself is an announcement *about* a presentation, and not the presentation slides or a transcript, it fits best under the general category for investor-related news that isn't a formal earnings release or capital change. Given the options, 'Investor Presentation (IP)' is the closest fit as it relates to investor outreach, even though it's an announcement of participation rather than the presentation itself. If the document were the actual presentation slides, IP would be certain. As a news item about an upcoming investor event, it is highly relevant to investor relations. Alternatively, since it is a general corporate news item distributed via EQS, 'RNS' (Regulatory Filings/General Regulatory Announcements) is a fallback. Given the specific focus on an investor conference presentation, IP is more descriptive than RNS.
2024-01-04 English
Formycon announces EMA acceptance of the MAA for FYB203, a biosimilar candidate to Eylea (Aflibercept)
Regulatory Filings Classification · 100% confidence The document is a press release dated December 27, 2023, announcing that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Formycon's biosimilar candidate FYB203. This is a specific regulatory event update concerning a product application review, not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a general shareholder vote result (DVA). Since it is a specific regulatory announcement that doesn't fit the other specialized categories (like DIRS, DIV, CAP, etc.), it falls best under the general 'Regulatory Filings' category (RNS) as a significant, non-financial regulatory update disseminated via a news service (EQS-News). The document length (7286 chars) is substantial enough that it is the primary content, not just a brief announcement of an attached report.
2023-12-27 English
Health Canada approves FYB201/Ranopto (Ranibizumab), a biosimilar to Lucentis
Regulatory Filings Classification · 100% confidence The document is a press release dated December 7, 2023, announcing that Health Canada has granted a 'Notice of Compliance' (NOC) for FYB201/Ranopto®, a biosimilar drug. This is a specific corporate event announcement related to regulatory approval in a key market (Canada). It is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a transcript (CT). Since it is a specific announcement of a regulatory milestone (approval), it fits best under the general category of Regulatory Filings (RNS), as it is a news release disseminated via a service like EQS News, which handles regulatory announcements, and it doesn't fit any of the more specific non-financial announcement codes (like MANG, DIRS, DIV, etc.). While it relates to a regulatory event, it is not the formal regulatory filing itself, but rather the public announcement of that event, making RNS the most appropriate general classification for this type of news release.
2023-12-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.